%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Pharma News
10/23/2026
BreakingCataractIOLPharmaPremiumRetinaRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision
Swiss company Roche reported Oct. 22 that Q3-2026 Vabysmo sales were CHF 1.1 billion ($1.4 billion, converted for Sept. 20, 2026) a 13 percent increase over CHF 996 million in Q3-2025. US Vabysmo s...
10/23/2026
BreakingPharmaRegulation
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours, o...
10/23/2026
BreakingPharmaPresbyopia
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the f...
10/23/2026
BreakingClinical TrialIndustryPharmaRetina
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
10/23/2026
BreakingPharmaRegulationRetina
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland
Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those nati...
10/21/2026
Dry EyeNewsletterPharmaRevenue
Miticides to Treat Dry Eye Climbing Toward $1 Billion in Annual Sales
Tarsus Pharmaceuticals is behind the rapid growth of the miticide category of dry-eye related pharmaceuticals in the US. Market Scope expects US sales in the miticide category to soon exceed $1 bil...
10/21/2026
NewsletterPharmaRegulation
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours, o...
10/21/2026
DealsNewsletterPharmaRetina
Glaukos Licenses Tri-specific Retinal Candidate from RevOpsis
Glaukos announced Oct. 8 that it had licensed from RevOpsis Therapeutics exclusive rights to RO-104, a novel tri-specific biologic candidate targeting wet age-related macular degeneration, diabetic...
10/21/2026
NewsletterPharmaRegulation
Bausch + Lomb Receives FDA Warning Letter for Tampa, Florida, Plant, Citing Persistent Contamination
The US FDA sent Bausch + Lomb a warning letter Sept. 4 regarding significant violations observed at its manufacturing plant in Tampa, Florida, during an FDA inspection in March 2026. The Tampa loca...
10/16/2026
BreakingClinical TrialPharmaRetina
Merck Sees Mixed Results at One Year in Pivotal Trial of Remigromig in DME
Merck presented one-year results from remigromig’s pivotal Phase IIb/III BRUNELLO trial at the 2026 meeting of the American Academy of Ophthalmology (AAO), held Oct. 10-12 in New Orleans, Louisiana...
10/16/2026
BreakingIndustryPharmaSurgical
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
10/16/2026
BreakingPharmaRegulationRetinaUveitis
US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027
Genentech, a member of the Roche group, reported Oct. 10 that the US FDA had accepted the biologics license application (BLA) for vamikibart, an intravitreal IL-6 inhibitor candidate for uveitic ma...
10/9/2026
BreakingClinical TrialPharmaRegulationRetina
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate
Surrozen announced on Oct. 2 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of SZN-8141, a bifunctional Wnt agonis...
10/2/2026
BreakingDry EyePharmaRegulation
Aldeyra to File Formal Dispute with US FDA over Reproxalap Rejection
Aldeyra Therapeutics reported Sept. 29 that it would submit a formal dispute resolution request with the US FDA over the rejection of reproxalap, a topical treatment candidate for dry eye disease. ...
10/2/2026
BreakingCornealIndustryPharma
Claris Bio Establishes Corporate Headquarters in San Francisco
Claris Bio reported Sept. 24 that it had moved its corporate headquarters from Jersey City, New Jersey, to San Francisco, California. Its new home is at 701 Gateway Blvd., Suite 250, South San Fran...
9/25/2026
BreakingPharmaRegulation
Bausch + Lomb Receives FDA Warning Letter for Tampa, Florida, Plant, Citing Persistent Contamination
The US FDA sent Bausch + Lomb a warning letter Sept. 4 regarding significant violations observed at its manufacturing plant in Tampa, Florida, during an FDA inspection in March 2026. The Tampa loca...
9/22/2026
Clinical TrialNewsletterPharmaRegulationRetina
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
9/22/2026
EuropeNewsletterPharmaRetinaSingle-Use
Oxford Eye Hospital Initiative Cuts IVT Injection Waste and Costs
Britain’s Oxford Eye Hospital reported Aug. 24 that an initiative there to change the way intravitreal (IVT) injections are administered has eliminated tons of associated single-use product waste a...
9/22/2026
CornealDealsDry EyeFundingNewsletterPharmaPresbyopiaRefractiveRetina
Ingenia Leads Latest Fundraising with $42.3 Million Initial Public Offering
Ingenia Therapeutics led recent ophthalmic fundraising efforts, which totaled $57.3 million in the past four weeks.
9/22/2026
Dry EyeNewsletterPharmaRefractive
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
9/22/2026
AIChinaDealsDry EyeEuropeGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRetinaSurgical
September 2026 Ophthalmic News Briefs
UK-based Rayner reported Sept. 7 the launch of its Galaxy Hydrophobic spiral IOL. The lens will be available commercially in the EU in Q4-2026. The original Galaxy spiral IOL, a full range of visio...
9/18/2026
BreakingPharmaRegulationRetina
Surrozen Submits IND Application for Dual-Acting SZN-8141 in DME
Surrozen announced Sept. 8 that it had submitted an investigational new drug (IND) application to the US FDA to launch a clinical trial of SZN-8141, a bifunctional Wnt agonist and vascular endothel...
9/18/2026
BreakingChinaDealsGlaucomaPharmaRegulation
Chinese Regulators Accept NDA for Glaucoma Drop from Nicox, Ocumension
France’s Nicox and partner Ocumension Therapeutics, of China, announced Sept. 11 that China’s National Medical Products Administration (NMPA) had accepted the new drug application (NDA) for NCX 470...
9/18/2026
BreakingPharmaRegulationRetina
Belite Bio Submits NDA in Japan for Oral Tinlarebant in Stargardt
Belite Bio announced Sept. 8 that it had submitted a new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant, to Japan’s Ministry of Health, Labour, and Welfare. Tinlareb...
9/4/2026
BreakingCataractGlaucomaIOLIndustryPharmaSurgical
SpyGlass Celebrates Grand Opening of New Irvine, California, Headquarters
SpyGlass Pharma celebrated the grand opening of its new Irvine, California, headquarters on Aug. 27, as the company continues to expand. SpyGlass was initially founded in Irvine in 2019 by Malik Y....
8/28/2026
BreakingDealsGlaucomaPharmaRegulation
US FDA Accepts NDA for Glaucoma Drop from Nicox and Kowa, Sets PDUFA Date of April 30, 2027
France’s Nicox announced Aug. 27 that the US FDA had accepted the new drug application (NDA) for NCX 470 (bimatoprost grenod; also known as K-911) and set a Prescription Drug User Fee Act (PDUFA) t...
8/28/2026
BreakingClinical TrialDry EyePharma
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
8/28/2026
BreakingGlaucomaPharma
Santen Launches Rhopressa Glaucoma Drops in Japan
Santen announced Aug. 17 that it had launched Rhopressa (netarsudil ophthalmic solution) 0.02%, an eye drop targeting glaucoma and ocular hypertension, in Japan. The treatment gained marketing appr...
8/28/2026
BreakingPharmaRegulationRetina
Japan Grants Orphan Status to Alkeus’ Oral Gildeuretinol for Stargardt
Alkeus Pharmaceuticals announced Aug. 24 that Japan’s Ministry of Health, Labour, and Welfare had granted orphan drug status to gildeuretinol, its oral therapy candidate for Stargardt disease. In J...
8/21/2026
BiosimilarsBreakingDiagnosticIOLPharmaRetinaRevenueSurgical
Quarterly Revenue Roundup for Carl Zeiss Meditec and Santen
German company Carl Zeiss Meditec reported Aug. 6 that its ophthalmic device revenue for the three months ended June 2026 (the third quarter of its fiscal 2025/2026 year) was €437.6 million ($499.7...
8/20/2026
MeetingNewsletterPharmaRetina
Retinal Treatment Durability Takes Center Stage at ASRS Meeting
Treatment durability was a recurring theme in sessions throughout the 2026 annual meeting of the American Society of Retina Specialists. Day 2 of the meeting began with a session titled, “Beyond An...
8/20/2026
Clinical TrialGlaucomaIndustryNewsletterPharma
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...
8/20/2026
DealsDry EyeNewsletterPharma
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...
8/20/2026
CataractChinaClinical TrialCornealDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIOLNewsletterPharmaRetinaSurgical
Tarsus Leads Latest Fundraising with $125 Million Private Placement
Tarsus Pharmaceuticals led recent ophthalmic fundraising efforts with a $125 million private placement for clinical development and commercial activities. Financing announced in the past four weeks...
8/20/2026
AllergyCataractChinaDealsDiagnosticDry EyeEuropeFundusGene TherapyGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRefractiveRegulationRetinaSurgical
August 2026 Ophthalmic News Briefs
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL delivery system in the US. The inserter is available now with the enVista Aspire intermediate-optimized mon...
8/14/2026
BreakingPharmaRegulationRetina
US FDA Accepts NDA for Belite’s Oral Stargardt Candidate, Grants Priority Review
Belite Bio announced Aug. 11 that the US FDA had accepted its new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant. The agency granted priority review, and set a Presc...
8/14/2026
BreakingCataractDry EyeGlaucomaIOLOcular CancerPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI
Alcon reported Aug. 10 that its Q2-2026 net sales totaled $2.8 billion, an 8 percent increase over $2.6 billion in Q2-2025. Alcon also announced that it had discontinued work on the PowerVision Flu...
8/14/2026
BreakingChinaDealsGlaucomaPharmaRegulation
Nicox Partner Ocumension Submits NDA in China for Glaucoma Drop
France’s Nicox announced Aug. 10 that its partner Ocumension Therapeutics, of China, had submitted a new drug application (NDA) to China’s National Medical Products Administration for NCX 470, a ni...
8/7/2026
BreakingDealsDry EyePharmaRetina
Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million
Tarsus Pharmaceuticals, maker of Xdemvy, announced Aug. 6 that it would acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million. Under the deal, Tarsus will pay $450 milli...
8/7/2026
BiosimilarsBreakingCataractIOLLaserPharmaRetinaRevenueSurgicalThyroid Eye Disease
Q2-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Astellas, Novartis, Lumibird, Ocular Therapeutix, and Xbrane
Regeneron, of Tarrytown, New York, reported July 30 that its Q2-2026 US revenue for Eylea HD and Eylea 2 mg was $1.0 billion, a 12 percent decrease from $1.15 billion in Q2-2025. Eylea HD accounted...
8/7/2026
BreakingDealsDry EyePharma
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...
8/7/2026
BreakingEuropePharmaRegulationRetina
Roche Receives Positive CHMP Opinion for Susvimo Sustained-Release Wet AMD Treatment
Swiss drugmaker Roche announced July 24 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for ...
8/7/2026
BreakingFundingGlaucomaPharmaRegulation
Nicox Partner Kowa Submits NDA to US FDA for Glaucoma Drop
France’s Nicox announced July 1 that its partner Kowa, of Japan, had submitted a new drug application to the US FDA for NCX 470, also known as K-911, a nitric oxide-donating bimatoprost eye drop ca...
7/31/2026
BreakingPharmaRegulationRetina
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
7/31/2026
BreakingCataractCornealDry EyeGene TherapyGlaucomaIOLMIGSPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...
7/24/2026
AIBreakingPharmaRegulation
Kalshi Offers Betting on Drug Development Timelines and Results
Prediction market Kalshi began on July 16 offering betting on a range of drug development milestones, ranging from clinical trial outcomes and timelines for submissions to US FDA decisions. The New...
7/24/2026
BreakingIndustryPharmaRetina
NovaBridge Biosciences Appoints Srishti Gupta, MD, as Chief Executive Officer
NovaBridge Biosciences announced June 29 that it had appointed Srishti Gupta, MD, as chief executive officer and a member of the company’s board of directors. The company said that Xi-Yong (Sean) F...
7/24/2026
BreakingIndustryPharmaRetina
Exonate Appoints Olav Hellebø as Chief Executive Officer
British company Exonate announced June 30 that it had appointed Olav Hellebø as chief executive officer. Exonate is developing EXN407, an eye drop candidate entering Phase IIb study for diabetic ey...
7/21/2026
GlaucomaLaserMIGSNewsletterPharmaRegulation
MACs Propose Limiting Coverage for iDose TR in Glaucoma Patients
Five Medicare administrative contractors (MACs) in the US are proposing to limit coverage for procedures implanting the Glaukos iDose TR in patients with glaucoma. The iDose TR is a drug-eluting in...
7/21/2026
CataractDiagnosticDry EyeEmergingNewsletterPharmaRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
7/21/2026
AICataractChinaDealsDiagnosticDigitalFundusGlaucomaIOLIndustryNewsletterPharmaRefractiveRegulationRetinaSurgical
July 2026 Ophthalmic News Briefs
Johnson & Johnson reported June 15 that it would invest more than $1 billion in its Jacksonville, Florida, operations to scale US-based manufacturing, packaging, and distribution for its Acuvue con...
7/17/2026
AllergyBreakingCataractPharmaRegulationRetina
US FDA Recalls 2.5 Million Bottles of Prednisolone Acetate Eye Drops
The US FDA has issued a Class II recall of more than 2.5 million bottles of prednisolone acetate 1% eye drops manufactured by Lupin Limited, citing the possibility of foreign particulate contaminat...
7/2/2026
BreakingGlaucomaPharmaRegulationSurgical
MACs Propose Limiting Coverage for iDose TR
Five Medicare administrative contractors (MACs) in the US are proposing to limit coverage for procedures implanting the Glaukos iDose TR in patients with glaucoma. The iDose TR is a drug-eluting in...
7/2/2026
BreakingPharmaRegulation
Supreme Court Ruling in Favor of Bayer May Shut Down Thousands of Roundup Lawsuits
German company Bayer won a landmark ruling in the US Supreme Court on June 25, when justices ruled 7-2 that federal pesticide laws preempt “failure-to-warn” claims made under state law. The plainti...
6/26/2026
BreakingGlaucomaPharma
Théa Pharma Launches Zolymbus Bimatoprost Gel for Glaucoma in the US
Théa Pharma, the Massachusetts-based subsidiary of France-based Théa, announced June 15 that it had launched Zolymbus (bimatoprost ophthalmic gel) 0.01% in the US. Thepreservative-free formulation ...
6/26/2026
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Samil for Vietnam
Taiwan-based Formosa Pharmaceuticals announced June 11 that it had expanded its licensing agreement with Samil Pharmaceuticals for clobetasol propionate 0.05% eye drops for postsurgical inflammatio...
6/26/2026
BreakingDry EyePharma
Ocusoft Introduces Retaine Ultra PF Preservative-Free Artificial Tears
Ocusoft, of Rosenberg, Texas, announced on June 17 the launch of Retaine Ultra PF, a lubricating eye drop available in a preservative-free multi-dose bottle. Its active ingredients include polyethy...
6/26/2026
BreakingGlaucomaIndustryPharma
Essential Pharma Appoints Becki Morison as Chief Executive Officer
UK-based Essential Pharma announced June 18 that it had appointed Becki Morison as chief executive officer, effective July 1. Morison succeeds Simon Ball, who has served as interim CEO since Novemb...
6/19/2026
BreakingPharmaRegulationRetina
Belite Bio Completes Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced June 12 that it had completed its rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califo...
6/19/2026
BreakingGlaucomaIndustryPharmaRetina
Tavo Biotherapeutics Appoints Federico Grossi, MD, PhD, as CMO
Tavo Biotherapeutics, of Laguna Beach, California, announced June 2 that it had appointed Federico Grossi, MD, PhD, as chief medical officer (CMO). Grossi most recently was CMO of Unity Biotechnolo...
6/18/2026
NewsletterPharmaRegulation
US FDA Commissioner Makary Resigns After Rocky Year in Top Job
US FDA Commissioner Marty Makary, MD, MPH, resigned May 12 after a rocky year in the agency’s top job that saw mass layoffs, high-level resignations, and policy fights with lawmakers, drugmakers, a...
6/18/2026
FundingGlaucomaNewsletterPharmaRetinaSurgicalThyroid Eye Disease
Ethyreal Bio Leads Latest Fundraising with $101 Million in Series A
Ethyreal Bio led recent ophthalmic fundraising efforts with $101 million in a Series A financing to advance its subcutaneous candidate for thyroid eye disease. Financing announced in the past four ...
6/18/2026
NewsletterPharmaRegulationRetina
Outlook Therapeutics Resubmits BLA for Lytenava After Winning FDA Appeal
Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...
6/18/2026
AIAllergyAmblyopiaCataractClinical TrialDealsDiagnosticIOLIndustryLaserMicroscopesMyopiaNewsletterOptometryPharmaRegulationRetinaSingle-UseSurgical
June 2026 Ophthalmic News Briefs
UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new OVD formulated with a high molecular weight to optimize space creation and ease of removal. Ophteis Cohesive is packaged at 1....
6/12/2026
AllergyBreakingDry EyePharma
Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis
Harrow reported June 10 that it had relaunched Verkazia (cyclosporine ophthalmic emulsion, 0.1%) in the US for the treatment of vernal keratoconjunctivitis (VKC). VKC is a serious allergic eye dise...
6/12/2026
BreakingCataractPharmaRegulation
Apotex Gains Health Canada Approval for Iheezo Ophthalmic Anesthesia
Toronto’s Apotex announced May 26 that it had secured Health Canada marketing approval for Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical anesthetic indicated for ocular surface...
6/5/2026
BreakingClinical TrialPharmaRetina
Oculis Scraps DME Eye Drop Program after Phase III Failure
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
6/5/2026
BreakingPharmaRegulationRetina
Outlook Therapeutics Resubmits BLA for Lytenava After Winning Appeal with FDA
Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...
6/5/2026
BreakingPharmaRegulation
US FDA Leadership Shakeup Continues as Drug Division Chief Exits
The US FDA’s drug evaluation division has another new leader. Michael Davis, MD, PhD, has been named acting director of the Center for Drug Evaluation and Research (CDER), according to the FDA’s we...
5/22/2026
BreakingCataractIOLPharma
Annual and Quarterly Ophthalmic Revenue Roundup for Santen, Carl Zeiss Meditec, Harrow, RxSight, ANI, and Lensar
Japan-based Santen reported May 12 that its revenue for its fiscal year 2025, which ended March 31, 2026, was JPY 291.6 billion ($1.8 billion, calculated for March 31, 2026), a 2.8 percent decline ...
5/14/2026
GlaucomaNewsletterPharma
Generics, New Drug Classes, Sustained Release Dosing Shape Glaucoma Pharma Market
The glaucoma pharmaceuticals market is showing signs of emerging from its prolonged revenue slump. One cycle of conversions from proprietary drugs to generic drugs is nearing an end, and a new cycl...
5/15/2026
BreakingDeviceDry EyeGlaucomaPharmaPresbyopiaRevenue
Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz
Tarsus Pharmaceuticals, of Irvine, California, reported May 6 that its Q1-2026 revenue for Xdemvy was $145.4 million, an 85 percent increase over $78.3 million in Q1-2025. Xdemvy (lotilaner ophthal...
5/15/2026
BreakingDevicePharmaRegulation
US FDA Commissioner Makary Resigns After Rocky Year in Top Job
US FDA Commissioner Marty Makary, MD, MPH, resigned May 12 after a rocky year in the agency’s top job that saw mass layoffs, high-level resignations, and policy fights with lawmakers, drugmakers, a...
5/14/2026
ChinaDealsGlaucomaNewsletterPharma
Santen to Market Five of AbbVie’s Glaucoma Drops in Mainland China
Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...
5/14/2026
FundingGene TherapyNewsletterPharmaRetinaThyroid Eye Disease
Viridian Leads Latest Fundraising with $250 Million in Public Offerings
Viridian Therapeutics led recent ophthalmic fundraising efforts with $250 million in public offerings of convertible notes and Series B stock to advance its TED candidates. Financing announced in t...
5/8/2026
BreakingDealsGlaucomaPharmaRetina
Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion
German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...
5/1/2026
BreakingCataractCornealGlaucomaIOLLaserPharmaRetinaRevenueSurgical
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...
5/1/2026
BreakingDealsPharmaRetina
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...
5/1/2026
BreakingPharmaRegulationRetina
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced April 21 that it had initiated a rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califor...
5/1/2026
BreakingCataractClinical TrialIOLPharma
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain
Israel’s PRF Technologies and its majority-owned subsidiary LayerBio reported on April 28 that the US FDA had signed off on their investigational new drug (IND) application, allowing LayerBio to pr...
5/1/2026
BreakingCornealDry EyePharmaStudy
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease
Taiwan’s Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have teamed up to address unmet needs in corneal and ocular surface disease, Formosa announced April 30. The partner...
4/24/2026
BreakingPharmaRetinaRevenue
Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion
Swiss company Roche reported April 23 that Vabysmo sales in Q1-2026 were CHF 1.024 billion ($1.3 billion, calculated for March 31, 2026), up 13 percent in constant currency from CHF 1.018 billion i...
4/24/2026
BreakingPharmaRegulationRetina
US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO
Genentech announced April 9 that the US FDA had approved the extension of dosing intervals for Vabysmo (faricimab-svoa) beyond six months for patients with macular edema due to retinal vein occlusi...
4/24/2026
BreakingPharmaPresbyopiaRegulation
Lenz Submits Marketing Application for Vizz Presbyopia Drop in the UK
Lenz Therapeutics announced April 20 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for Vizz, an eye drop targeting pres...
4/24/2026
BreakingChinaDealsGlaucomaPharma
Santen to Market Five of AbbVie’s Glaucoma Drops in China
Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...
4/21/2026
DeviceFundingIndustryNewsletterPharma
J&J Continues to Reduce JLABS Footprint with Exit from New York
Johnson & Johnson is stepping away from its JLABS incubator site in New York, reducing its JLABS locations in the US to those in San Diego, San Francisco, and Boston. The New York site opened in 20...
4/21/2026
FundusGene TherapyGlaucomaNewsletterPharmaRetina
Life Bio Leads Latest Fundraising with $80 Million in Series D Round
Life Biosciences led recent ophthalmic fundraising efforts with $80 million in Series D funding to advance its cell rejuvenation therapy pipeline. Financing announced in the past four weeks totaled...
4/21/2026
IndustryNewsletterPharmaPresbyopia
Tenpoint Launches Yuvezzi Drops for Presbyopia in US
Tenpoint Therapeutics announced March 30 that it had launched Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for presbyopia in the US. Tenpoint, with offices in London,...
4/21/2026
BiosimilarsCataractCell TherapyChinaClinical TrialCornealDiagnosticDigitalDry EyeIOLIndiaIndustryMicroscopesNewsletterPharmaRegulationRetina
April 2026 Ophthalmic News Briefs
Swiss ophthalmic diagnostics company Haag-Streit announced March 31 the global launch of its Metis 3D Digital Heads-Up Module (Metis HU). The system was launched in the US in October 2025. Metis HU...
4/17/2026
BreakingDry EyePharmaRegulation
KC Pharmaceuticals Recalls 3.1 Million Eye Drop Bottles over Sterility Concerns
The US FDA reported in March that more than 3.1 million bottles of over-the-counter eye drops sold at major US retailers—including CVS, Walgreens, Kroger, and Rite Aid—had been recalled over steril...
4/17/2026
BreakingPharmaRegulationRetina
US FDA Grants Orphan Drug Status to Drug Farm’s ROSAH Candidate
Drug Farm, of Shanghai, China, announced March 26 that the US FDA had granted orphan drug status to DF-003, an oral alpha kinase 1 (ALPK1) inhibitor targeting the rare genetic disease ROSAH syndrom...
4/17/2026
BreakingEmergingPharmaRegulationRetina
US FDA Grants Orphan Drug Status to SignaBlok’s ROP Candidate
SignaBlok, of Shrewsbury, Massachusetts, announced March 26 that the US FDA had granted orphan drug status to its TREM-1 peptide inhibitor targeting retinopathy of prematurity (ROP). Orphan drug de...
4/10/2026
BreakingPharmaRegulationRetina
US FDA Approves Eylea HD for Extended Dosing Intervals up to 5 Months
Regeneron announced April 2 that the US FDA had approved the extension of dosing intervals for Eylea HD (aflibercept 8 mg) up to every 20 weeks for patients with wet age-related macular degeneratio...
4/10/2026
BreakingIndustryPharmaPresbyopia
Tenpoint Appoints Stephen S. Lane, MD, as Chief Medical Officer
Tenpoint Therapeutics announced April 7 that it had appointed Stephen S. Lane, MD, as chief medical officer (CMO). Most recently, Lane was CMO and head of medical safety at Alcon. He is a past pres...
4/3/2026
BreakingDealsPharmaRetina
Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth
Biogen reported March 31 that it had agreed to acquire Apellis Pharmaceuticals, maker of Syfovre, for about $5.6 billion in cash to expand its portfolio of rare-disease medicines. Under the deal, ...
4/3/2026
BreakingPharmaPresbyopia
Tenpoint Launches Yuvezzi Drops for Presbyopia in US
Tenpoint Therapeutics announced March 30 that it had launched Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for presbyopia in the US. Tenpoint, with offices in London,...
4/3/2026
BreakingCataractPharmaRegulation
Health Canada Approves Clobetasol Propionate Eye Drops for Postsurgical Pain, Inflammation
Canada’s Apotex announced March 25 that regulators there had approved Clobivis (clobetasol propionate ophthalmic suspension, 0.05%) for the treatment of postoperative inflammation and pain followin...
3/27/2026
BreakingDeviceFundingIndustryPharma
J&J Continues to Reduce JLABS Footprint with Exit from New York
Johnson & Johnson is stepping away from its JLABS incubator site in New York, reducing its JLABS locations in the US to those in San Diego, San Francisco, and Boston. The New York site opened in 20...
3/24/2026
DeviceNewsletterPharmaRevenue
Ophthalmic Company Revenue Down 1.8 Percent in Q4-2025; Seven Firms See Declines
Ophthalmic manufacturer revenue in Q4-2025 totaled $11.8 billion. Revenue decreased 1.8 percent from the same quarter in 2024 and increased 2.5 percent from Q3-2025. The total includes Market Scope...
3/24/2026
NewsletterPharmaRegulationRetina
US FDA Rejects Chiesi’s Idebenone for LHON, Asks for More Clinical Data
Chiesi reported March 5 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON)...
3/24/2026
Dry EyeNewsletterPharmaRegulation
US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Citing Trial Failures
Aldeyra Therapeutics reported March 17 that the US FDA had issued a third complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap in dry eye disease. Alde...
3/24/2026
Clinical TrialCornealGene TherapyGlaucomaMyopiaNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, March 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
3/24/2026
Clinical TrialNewsletterPharmaRegulation
US FDA Will Drop Two-Study Requirement for New Drug Approvals
The US FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, according to a journal article published Feb. 18. Going forward, the agency’s “defaul...
3/20/2026
BreakingDry EyePharmaRegulation
US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Citing Trial Failures
Aldeyra Therapeutics reported March 17 that the US FDA had issued a third complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment for dry e...
3/13/2026
BreakingPharmaRegulationRetina
US FDA Rejects Chiesi’s Idebenone for LHON, Asks for More Clinical Data
Chiesi reported March 5 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON)...
3/13/2026
BreakingEuropePharmaPresbyopiaRegulation
Lenz Submits Marketing Application for Vizz Presbyopia Drop in Europe
Lenz Therapeutics announced March 10 that it had submitted a marketing authorization application to the European Medicines Agency for Vizz, an eye drop targeting presbyopia. Vizz (aceclidine ophtha...
3/13/2026
BreakingGlaucomaIndustryPharma
Qlaris Bio Appoints Fred Guerard, PharmD, as President and CEO
Qlaris Bio announced March 10 that it had appointed Fred Guerard, PharmD, as president and chief executive officer, effective March 1. Guerard will also join the company’s board of directors. He mo...
3/6/2026
BiosimilarsBreakingCataractEuropeIOLPharmaRetinaRevenueSurgicalUveitis
Ophthalmic Quarterly and 2025 Revenue for Carl Zeiss Meditec, Harrow, RxSight, ANI, and Xbrane
Million Carl Zeiss Meditec reported Feb. 12 that ophthalmology revenue for the last three months of 2025, the first quarter of its fiscal year 2025/2026, totaled €356.9 million ($419.2 million, con...
3/6/2026
BreakingCataractClinical TrialPharma
US FDA Gives Green Light to Phase III Trial of Harrow’s Triesence for Post-op Inflammation and Pain
Nashville, Tennessee-based Harrow reported on March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase III trial of Tri...
2/27/2026
BreakingPharmaPresbyopiaRegulation
US FDA Accepts sNDA for Opus’ Presbyopia Candidate, Sets PDUFA Date of Oct. 17, 2026
Commercial partners Viatris and Opus Genetics reported Feb. 25 that the US FDA had accepted the supplemental new drug application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%), targeti...
2/27/2026
BreakingCataractDry EyeOcular CancerPharmaRetinaRevenueSurgical
2025 Ophthalmic Revenue Roundup for Alcon, Apellis, Tarsus, and Immunocore
Alcon reported Feb. 24 that its full year 2025 net sales totaled $10.3 billion, a 5 percent increase over $9.8 billion in 2024. Q4-2025 sales were $2.7 billion, a 9 percent increase over $2.5 billi...
2/23/2026
GlaucomaMeetingNewsletterPharmaSurgical
G360 Meeting Sets Fundraising Record, Shines Spotlight on Range of Stakeholders
The 2026 Glaucoma 360 meeting set a record for fundraising, with its gala taking in $715 thousand in donations and the New Horizons Forum bringing in another $462 thousand from corporate sponsorshi...
2/27/2026
BreakingDealsPharmaRetina
Outlook Grants Mediconsult Rights to Market Lytenava in Switzerland
Outlook Therapeutics announced Feb. 19 an agreement granting Mediconsult exclusive commercial distribution rights for Lytenava (bevacizumab gamma) in the Swiss market. Financial details were not di...
2/27/2026
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Arrotex for Australia, New Zealand
Taiwan-based Formosa Pharmaceuticals announced Feb. 23 that it had agreed to license to Arrotex Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inf...
2/27/2026
AllergyBreakingClinical TrialPharmaRegulation
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate
NexEos Bio, of Malvern, Pennsylvania, reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial...
2/27/2026
BreakingClinical TrialPharmaPresbyopiaRegulation
US FDA Gives Green Light to Phase II Trial of Cloudbreak’s Presbyopia Drop Candidate
The financial website TipRanks reported on Feb. 15 that the US FDA had signed off on Cloudbreak Pharma’s investigational new drug (IND) application, allowing the company to proceed with a Phase II ...
2/23/2026
CataractNewsletterPharma
Dropless Cataract Surgery Gets a Boost as Interest, Data Align
Dropless cataract surgery continues to gain traction as surgeons seek to simplify postoperative care and im-prove patient adherence—but the meaning and adoption of the practice vary significantly. ...
2/23/2026
GlaucomaNewsletterPharmaRegulation
US FDA Approves Re-administration of Glaukos’ iDose TR
Glaukos announced Jan. 28 that the US FDA had approved a supplement to its new drug application allowing for re-administration of iDose TR, the company’s intracameral travoprost implant for glaucom...
2/23/2026
NewsletterPharmaPresbyopiaRegulation
US FDA Approves Tenpoint’s Yuvezzi Drops for Presbyopia
Tenpoint Therapeutics announced Jan. 28 that the US FDA had approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for presbyopia. The company said it expects to launc...
2/23/2026
NewsletterPharmaRegulation
New US Law Institutes Major Pharmacy Benefit Manager Reforms in 2029
The $1.2 trillion US spending package signed into law on Feb. 3 includes major reforms to pharmacy benefit manager (PBM) practices. These provisions go into effect for health plan years that come a...
2/23/2026
CataractClinical TrialCornealGene TherapyGlaucomaIOLNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, February 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
2/23/2026
Clinical TrialNewsletterPharmaRegulationRetina
Ocular Therapeutix Reports Positive Results for Axpaxli vs. Eylea in Phase III Wet AMD Trial
Ocular Therapeutix reported on Feb. 17 positive topline results in the SOL-1 Phase III superiority trial of Axpaxli vs. Eylea (aflibercept) in wet age-related macular degeneration (AMD). Axpaxli, a...
2/23/2026
DeviceEuropeIndiaNewsletterPharmaRegulation
EU-India Free Trade Agreement to Phase in Lower Pharma and Device Tariffs
A free trade agreement reached Jan. 27 by the European Union and India will reduce or eliminate tariffs on about 90 percent of goods, including pharmaceuticals and medical devices, between the two ...
2/20/2026
BreakingClinical TrialPharmaRegulation
US FDA Will Drop Two-Study Requirement for New Drug Approvals
The US FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, according to a journal article published Feb. 18. Going forward, the agency’s “defaul...
2/20/2026
BreakingClinical TrialPharmaRegulationRetina
Ocular Therapeutix Reports Positive Results for Axpaxli vs. Eylea in Phase III Wet AMD Trial
Ocular Therapeutix reported on Feb. 17 positive topline results in the SOL-1 Phase III superiority trial of Axpaxli vs. Eylea (aflibercept) in wet age-related macular degeneration (AMD). Axpaxli, a...
2/12/2026
BreakingPharmaRegulation
New US Law Institutes Major Pharmacy Benefit Manager Reforms in 2029
The $1.2 trillion US spending package signed into law on Feb. 3 includes major reforms to pharmacy benefit manager (PBM) practices. These provisions go into effect for health plan years that come a...
2/6/2026
BreakingPharmaRetinaRevenue
Quarterly and 2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Novartis, and Astellas
Swiss company Roche reported Jan. 29 that global sales of Vabysmo for 2025 were CHF 4.1 billion ($5.2 billion, converted Dec. 25, 2025), a 6 percent increase on a reported basis (+12 percent cc) ov...
2/6/2026
BreakingCataractDry EyePharmaRegulationRetina
Harrow Ends Compounded Product Sales in California, Plans to Sell All Products Under Harrow Label
Harrow reported Feb. 2 that it had stopped selling compounded products in California through its ImprimisRx subsidiary on Feb. 1, after settling a disciplinary action brought by the California Boar...
1/30/2026
BreakingDeviceEuropeIndiaPharmaRegulation
EU-India Free Trade Agreement to Phase in Lower Pharma and Device Tariffs
A free trade agreement reached Jan. 27 by the European Union and India will reduce or eliminate tariffs on about 90 percent of goods, including pharmaceuticals and medical devices, between the two ...
1/30/2026
BreakingPharmaRegulation
US FDA Rolls Out PreCheck Program to Speed Approval of Drug Manufacturing Plants
The US FDA announced Jan. 21 that it would begin accepting applications on Feb. 1, 2026, for its new PreCheck Pilot Program to improve the regulatory process for US manufacturing facilities. The ag...
1/23/2026
BreakingEuropePharmaRegulationRetina
Eylea 8 mg Gains EU Approval to Treat Macular Edema Following RVO
German drugmaker Bayer announced Jan. 16 that the European Commission had approved Eylea 8 mg, known as Eylea HD in the US, to treat patients with visual impairment due to macular edema following r...
1/23/2026
BreakingEmergingFundingPharmaRetina
BioAge Enters Ophthalmology with Oral NLRP3 Inhibitor Candidate for DME
BioAge Labs announced Jan. 20 that it would expand development of BGE-102, an orally administered NLRP3 inhibitor, into ophthalmology with a proof-of-concept study in diabetic macular edema (DME). ...
1/21/2026
NewsletterPharmaRegulation
2025 in Review: Turmoil Reigns at US FDA, with Leadership Shuffling and High-Level Exits
A year of upheaval at the US FDA began with what amounted to a gag order on staffers from President Donald Trump and ended with the fifth person in a year taking charge of the agency’s drug evaluat...
1/21/2026
NewsletterPharmaRetina
2025 in Review: Encelto for MacTel Nabs Many Firsts, Opens New Area of Study
US FDA approval of Encelto in March 2025 handed Neurotech a cluster of firsts. It was the first therapy approved to treat macular telangiectasia type 2 (MacTel), the first encapsulated cell therapy...
1/16/2026
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Samil for South Korea
Taiwan-based Formosa Pharmaceuticals announced Jan. 12 that it had agreed to license to Samil Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical infla...
1/16/2026
AmblyopiaBreakingGlaucomaIndustryPharma
Nanodropper, Now Mu Medical, Plans Combination with Bedo and Viseon
Nanodropper, of Rochester, Minnesota, announced Jan. 9 that it was now operating as Mu Medical and planned to combine with Bedo Solutions and Viseon Labs under the new umbrella. Nanodropper was fou...
12/26/2025
BreakingDry EyeGenericsPharmaRegulation
Amneal Gains US FDA Approval for Generic Version of Restasis for Dry Eye
Amneal Pharmaceuticals announced Dec. 1 that it had received US FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. C...
12/26/2025
BreakingCataractGenericsGlaucomaPharmaRegulation
Alembic Gains US FDA Approval for Generic of Bausch + Lomb’s Zylet
India’s Alembic Pharmaceuticals announced Dec. 11 that the US FDA had approved the abbreviated new drug application for its combination eye drop of loteprednol etabonate and tobramycin, referencing...
12/19/2025
BreakingDry EyePharmaRegulation
US FDA Extends Action Date on Aldeyra’s Reproxalap to March 2026
Aldeyra Therapeutics reported Dec. 15 that the US FDA had extended the Prescription Drug User Fee Act (PDUFA) target action date for dry eye drop candidate reproxalap to March 16, 2026. The new dru...
12/19/2025
BreakingDealsEuropeGlaucomaPharma
NTC Acquires Ophthalmology Business of Pharmathen
Italy-based NTC reported Dec. 10 that it had completed its acquisition of Pharmathen’s ophthalmology business. No financial details were provided. NTC’s main shareholder, Wise Equity, participated ...
12/16/2025
CataractEarningsGlaucomaNewsletterPharmaRetinaRevenueSurgical
Ophthalmic Company Revenue Drops 4.5 Percent in Third Quarter of 2025
Ophthalmic manufacturer revenue in Q3-2025 totaled $11.5 billion. Revenue decreased 4.5 percent from the same quarter in 2024 and decreased 1.8 percent from Q2-2025. The total includes Market Scope...
12/16/2025
Dry EyeNewsletterPharma
New Products Power Revenue Growth in Dry Eye Pharmaceuticals
Three new drugs shaking up the dry eye pharma market in the US are poised to drive revenue growth in the next five years. Xdemvy (lotilaner ophthalmic solution), from Tarsus Pharmaceuticals, has be...
12/16/2025
NewsletterPharmaRetina
Duke Becomes First Academic Center to Implant Encelto
Duke Eye Center, of Durham, North Carolina, reported Oct. 28 that it had become the first US academic medical center to implant Encelto. Encelto, an encapsulated cell-based gene therapy implant, is...
12/16/2025
NewsletterPharmaRegulationRetina
US FDA Approves Eylea HD for RVO, Plus Monthly Dosing in All Approved Indications
Regeneron Pharmaceuticals announced Nov. 19 that the US FDA had approved Eylea HD (aflibercept 8 mg) for macular edema following retinal vein occlusion (RVO), with dosing up to every eight weeks af...
12/16/2025
GlaucomaIOLIndustryNewsletterPharmaRetinaSurgical
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline
Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...
12/16/2025
NewsletterPharmaRegulation
CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement
Oncologist Richard Pazdur, MD, is reportedly retiring from his role as the US FDA’s director of the Center for Drug Evaluation and Research (CDER) after less than a month in the job. The FDA announ...
12/16/2025
CataractCornealDealsEmergingGene TherapyNewsletterOcular SurfacePharmaRetina
Emerging Companies Pursuing Ophthalmic Indications, December 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
12/5/2025
BreakingCataractDealsDry EyeFLACSGlaucomaIOLPharmaSurgical
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline
Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...
12/5/2025
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Rxilient for Countries in Southeast Asia
Taiwan-based Formosa Pharmaceuticals announced Dec. 3 that it had agreed to license to Rxilient Medical exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammatio...
12/5/2025
BreakingPharmaRegulation
CDER Chief Pazdur Retiring from US FDA; Makary Names Høeg as Replacement
Oncologist Richard Pazdur, MD, is reportedly retiring from his role as the US FDA’s director of the Center for Drug Evaluation and Research (CDER) after less than a month in the job. The FDA announ...
12/5/2025
BreakingDealsGlaucomaPharmaRegulation
Ocuvex Resubmits NDA to US FDA for Once-Daily Brimonidine Drop
India’s Sun Pharma Advanced Research Company (SPARC) announced Nov. 20 that its partner Ocuvex had resubmitted the new drug application to the US FDA for PDP-716, a once-daily eye drop formulation ...
11/21/2025
BreakingPharmaRegulationRetina
US FDA Approves Eylea HD for RVO, Plus Monthly Dosing in All Approved Indications
Regeneron Pharmaceuticals announced Nov. 19 that the US FDA had approved Eylea HD (aflibercept 8 mg) for macular edema following retinal vein occlusion (RVO), with dosing up to every eight weeks af...
11/19/2025
GenericsIndustryNewsletterPharma
Mallinckrodt Spins Off Generics Business, Rebrands as Keenova
Drugmaker Mallinckrodt announced Nov. 10 that it had completed the planned spinoff of its Par Health generic pharmaceuticals and sterile injectables businesses and had rebranded as Keenova Therapeu...
11/19/2025
NewsletterPharmaRegulation
Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research
The US FDA reported Nov. 11 that oncologist Richard Pazdur, MD, had been named director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the foundin...
11/14/2025
BreakingDry EyeFLACSGlaucomaIOLLaserMIGSOcular CancerPharmaRefractiveRetinaRevenueSurgical
Q3-2025 Ophthalmic Revenue Roundup for Alcon, Santen, Immunocore, STAAR, Harrow, and Five Others
Alcon reported Nov. 11 that its Q3-2025 net sales totaled $2.6 billion, a 6 percent increase over $2.4 billion in Q3-2024. Surgical net sales for implantables, consumables, and equipment/other were...
11/14/2025
BreakingPharmaRegulation
Richard Pazdur, MD, to Lead US FDA’s Center for Drug Evaluation and Research
The US FDA reported Nov. 11 that oncologist Richard Pazdur, MD, had been named director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the foundin...
11/14/2025
BreakingDealsPharmaPresbyopiaRegulation
Kwangdong Submits NDA in South Korea for Tenpoint’s Presbyopia Drop
Tenpoint Therapeutics announced Nov. 5 that Kwangdong Pharmaceutical had submitted a new drug application (NDA) to the Ministry of Food and Drug Safety in South Korea for Brimochol PF, a combinatio...
11/14/2025
BreakingIndustryPharmaUveitis
Mallinckrodt Spins Off Generics Business, Rebrands as Keenova
Drugmaker Mallinckrodt announced Nov. 10 that it had completed the planned spinoff of its Par Health generic pharmaceuticals and sterile injectables businesses and had rebranded as Keenova Therapeu...
11/7/2025
BreakingPharmaRegulationRetina
UK Accepts Conditional Marketing Application for Belite Bio’s Tinlarebant in Stargardt
Belite Bio announced Nov. 2 that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) had agreed to accept a conditional marketing authorization application for oral tinlarebant for ...
11/7/2025
BreakingPharmaRegulationRetina
Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)
Outlook Therapeutics reported Nov. 3 that it had resubmitted its biologics license application (BLA) to the US FDA for ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet age-rela...
11/7/2025
BreakingChinaDealsIndustryPharmaRetina
Visara Licenses Retinal Candidate to Everest for Greater China, Other Asian Countries
NovaBridge Biosciences announced Oct. 29 that its ophthalmic subsidiary, Visara, had licensed retinal treatment candidate VIS-101 to Everest Medicines for greater China, Singapore, South Korea, and...
11/7/2025
BreakingClinical TrialPharmaRetinaUveitis
Roche Reports Mixed Phase III Data for Vamikibart in Uveitic Macular Edema
Swiss drugmaker Roche reported on Oct. 16 mixed Phase III results for vamikibart, an IL-6 inhibitor being developed to address inflammation in uveitic macular edema (UME). Vamikibart, if approved, ...
10/31/2025
BreakingCataractDry EyeIOLPharmaRetinaRevenueSurgical
Q3-2025 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, Regeneron, Novartis
Bausch + Lomb reported Oct. 29 that its Q3-2025 revenue totaled $1.3 billion, a 7 percent increase over $1.2 billion in Q3-2024. Ophthalmic pharmaceuticals segment revenue was $330 million, an 8 pe...
10/31/2025
BreakingPharmaRegulationRetina
US FDA Rejects Eylea HD Prefilled Syringe over Inspection at Catalent Site
Regeneron reported in its Q3-2025 results on Oct. 28 that the US FDA had issued a complete response letter rejecting the supplemental biologics license application (sBLA) for a prefilled syringe of...
10/31/2025
BreakingChinaDealsPharmaRetina
China Medical System Acquires Rights in China to Novartis’ Beovu and Lucentis
China Medical System Holdings of Hong Kong announced Oct. 27 that its ophthalmic subsidiary CMS Vision had acquired exclusive distribution rights in mainland China for Novartis’ retinal treatments ...
10/31/2025
BreakingDealsPharma
Viatris, Locus Biosciences to Collaborate on Ophthalmic Antibacterial Therapies
Viatris and Locus Biosciences announced on Oct. 28 a research collaboration to develop novel products targeting ophthalmic bacterial infections. No financial details about the collaboration were di...
10/24/2025
BreakingDealsPharmaRetina
Santen Acquires Rights in South Korea to Novartis’ Beovu and Lucentis
Santen Pharmaceutical announced Oct. 20 that it had acquired exclusive distribution rights in South Korea for Novartis’ retinal treatments Beovu (brolucizumab) and Lucentis (ranibizumab). Both Beov...
10/24/2025
BreakingPharmaRegulationRetina
US FDA Grants Breakthrough Status to Nacuity’s Oral Candidate for RP
Nacuity Pharmaceuticals announced Oct. 2 that the US FDA had granted breakthrough therapy designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s oral treatment candidate for retinitis p...
10/24/2025
BreakingIndustryPharmaRetina
Valitor Appoints Gregory D. Kunst as Chief Executive Officer
Valitor, of Berkeley, California, announced Oct. 17 that it had appointed Gregory D. Kunst as chief executive officer and a member of the board of directors. Kunst replaces interim CEO Michael Ostr...
10/23/2025
BiosimilarsNewsletterPharmaRetina
Eylea Biosimilars Pushing at Market Gates, Could Disrupt Pricing
Aflibercept (Eylea) biosimilars are poised to have a significant impact on the exudative retinal disease pharmaceuticals market. The US saw its first Eylea biosimilar hit the market in Q4-2024, but...
10/23/2025
DealsFundingNewsletterPharmaRetina
Retinal Pharma Deals Drive Ophthalmic Fundraising in Q3-2025
The retinal pharmaceuticals sector was the most active for ophthalmic deals in Q3-2025 and accounted for $503.1 million. Across all ophthalmic sectors, we identified 16 transactions totaling $716.1...
10/23/2025
Cell TherapyCornealDiagnosticDry EyeFundingGene TherapyGlaucomaMyopiaNewsletterPharmaRetina
Ocular Tx Leads Latest Ophthalmic Fundraising with $475 Million Offering
Ocular Therapeutix led recent ophthalmic fundraising efforts with a $475 million underwritten public offering to advance its Axpaxli IVT implant candidate for retinal disease. Financing announced i...
10/23/2025
Gene TherapyNewsletterPharmaRetinaUveitis
Nonexudative Retinal Pharmaceuticals Market Seeing Early Signs of Diversification
Positive signs of growth for nonexudative retinal pharmaceuticals indicate that the industry is putting Europe’s rejection of complement inhibition in 2024 behind it. Manufacturers of complement in...
10/23/2025
Clinical TrialGene TherapyGlaucomaIOLLow VisionNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, October 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
10/23/2025
CataractDealsNewsletterPharma
Harrow Agrees to Reacquire Melt Pharmaceuticals
Harrow, of Nashville, Tennessee, reported Sept. 26 that it had agreed to reacquire Melt Pharmaceuticals, a clinical stage company developing sedation and analgesia medicines for short-duration medi...
10/23/2025
BiosimilarsCataractChinaCornealDealsDiagnosticDry EyeEuropeGene TherapyGenericsGlaucomaIndiaIndustryMIGSNewsletterPharmaPresbyopiaRegulationRetinaSurgical
October 2025 Ophthalmic News Briefs
Biotech Healthcare announced Sept. 23 that it had launched the Optiflex Xtense Comfort Plus extended-depth-of-focus (EDOF) intraocular lens at the ESCRS 2025 congress in Copenhagen, Denmark. Biotec...
10/17/2025
BreakingClinical TrialIndustryPharmaRetina
Ashvattha Names Bob Dempsey as Interim CEO
Ashvattha Therapeutics, of Redwood City, California, announced Oct. 14 that it had appointed Robert J. Dempsey as interim chief executive officer. The move follows the company’s release of positive...
10/10/2025
BreakingClinical TrialPharmaRegulationRetina
Oculis Accelerates Privosegtor Toward Pivotal Trials in Neuro-ophthalmology
Swiss company Oculis announced Oct. 6 that it will advance Privosegtor into a pivotal program for two indications in neuro-ophthalmology following a positive meeting with the US FDA. Privosegtor is...
10/10/2025
BreakingGenericsPharmaRegulation
Generic Drugmakers with US Sources Now Eligible for FDA Priority Review
The US FDA reported Oct. 3 that a new pilot program would speed the approval process for some generic drugmakers: They would be eligible for priority review if they conducted any required bioequiva...
10/10/2025
BreakingChinaPharmaRegulationRetina
Regulators in China Accept BLA for DME Candidate from Santen, RemeGen
Japan’s Santen Pharmaceutical and partner RemeGen announced Sept. 30 that China’s Center for Drug Evaluation had accepted the biologic license application (BLA) for retinal treatment candidate RC28...
10/10/2025
BreakingIndustryPharma
Harrow Names Frank Mullery as CEO of ImprimisRx Subsidiary
Harrow, of Nashville, Tennessee, announced Oct. 6 that Frank Mullery had been appointed chief executive officer of its ImprimisRx ophthalmic compounding subsidiary. Harrow said Mullery is a senior ...
10/3/2025
BreakingDry EyePharma
Harrow to Expand Access for All Program to Full Drug Portfolio
Harrow, of Nashville, Tennessee, reported Sept. 25 that it was expanding its Vevye Access for All program to the rest of its portfolio, making it easier and more affordable for patients to obtain t...
10/3/2025
BreakingPharmaPresbyopia
Lenz Launches Vizz Drops for Presbyopia in US
Lenz Therapeutics announced Sept. 30 that Vizz (aceclidine ophthalmic solution) 1.44% for presbyopia is now commercially available in the US. The company said its sales force was distributing sampl...
10/3/2025
BreakingPharmaRegulationRetina
Outlook Meets with US FDA, Plans to Resubmit BLA for Lytenava This Year
Outlook Therapeutics reported Sept. 29 that it had met with the US FDA regarding its latest rejection of the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation of...
10/3/2025
BreakingCataractDealsPharma
Harrow Agrees to Reacquire Melt Pharmaceuticals
Harrow, of Nashville, Tennessee, reported Sept. 26 that it had agreed to reacquire Melt Pharmaceuticals, a clinical stage company developing sedation and analgesia medicines for short-duration medi...
9/26/2025
BreakingPharmaRegulationRetina
US FDA Accepts Idebenone NDA for Priority Review, Sets PDUFA Date of Feb. 28, 2026
Chiesi announced Sept. 22 that the US FDA had accepted its new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON). Regulators set a Prescription Drug User F...
9/26/2025
BreakingGlaucomaPharmaRegulation
Amneal Gains US FDA Approval for Generic Bimatoprost 0.01% Eye Drop
Amneal Pharmaceuticals announced Sept. 23 that it had received US FDA approval for its generic bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL, and 7.5 mL), which references AbbVie’s Lumigan. B...
9/22/2025
NewsletterPharmaRegulationRetina
Annexon Aims to Make Difference in GA by Focusing on Neuroprotection
Excitement is growing around vonaprument (previously called ANX007), the drug that Annexon Biosciences is developing to treat geographic atrophy (GA). The international Phase III trial of the poten...
9/22/2025
NewsletterPharmaRegulation
FDA Looks to End Advisory Panel Meetings
US FDA leaders may end advisory panel meetings that weigh the risks and benefits of drugs, KFF Health News reported Sept. 12. The news outlet quoted George Tidmarsh, MD, PhD, head of the FDA’s Cent...
9/19/2025
BreakingPharmaRegulation
FDA Drug Official Looks to End Advisory Panel Meetings
US FDA leaders may end advisory panel meetings that weigh the risks and benefits of drugs, KFF Health News reported Sept. 12. The news outlet quoted George Tidmarsh, MD, PhD, head of the FDA’s Cent...
9/5/2025
BreakingEuropePharmaRegulationRetina
Roche Gains CE Marking for Port Delivery Platform, Branded Contivue in Europe
Swiss drugmaker Roche announced Sept. 4 that it had gained CE marking for its Port Delivery Platform, a refillable ranibizumab implant, which will be known as Contivue in Europe. The approval compr...
9/5/2025
BreakingPharmaRegulationRetina
Regulatory Panel in Japan Recommends Izervay for Approval in GA
A Japanese panel has recommended approval for Astellas Pharma’s avacincaptad pegol (known in the US as Izervay) to slow the progression of geographic atrophy (GA), according to a Pharma Japan repor...
9/5/2025
BreakingGlaucomaPharmaRegulation
Santen Gains Approval in Japan for Setaneo (Sepetaprost) Glaucoma Drops
Japan’s Santen announced Aug. 25 that it had gained manufacturing and marketing approval in Japan for Setaneo (sepetaprost 0.002%) eye drops for glaucoma and ocular hypertension. The prodrug, origi...
9/5/2025
BreakingPharmaRegulation
US FDA Begins Daily Reporting of Adverse Event Data
The US FDA announced Aug. 22 that it had begun daily publication of adverse event data, aiming to modernize its system for drug oversight and reaffirm its commitment to protecting public health. Th...
8/29/2025
BreakingPharmaRegulationRetina
US FDA Again Rejects Outlook’s Lytenava for Wet AMD, Citing Lack of Efficacy Evidence
Outlook Therapeutics reported Aug. 28 that the US FDA had issued a complete response letter rejecting the company’s resubmitted biologics license application (BLA) for Lytenava, an ophthalmic formu...
8/29/2025
BreakingPharmaRegulationRetina
Manufacturer Inspection Report Delays Two Eylea HD Target Action Dates
Regeneron announced Aug. 20 that the US FDA had extended the target action dates to Q4-2025 for two Eylea HD (aflibercept 8 mg) submissions. Reports from a recent inspection of a third-party manufa...
8/22/2025
BreakingCataractDealsDiagnosticIndustryPharmaPresbyopiaRetinaRevenueSurgical
Q2-2025 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, Opus, and Outlook
Alcon reported Aug. 19 that its Q2-2025 net sales totaled $2.6 billion, a 4 percent increase (+3 percent cc) over $2.5 billion in Q2-2024. Surgical net sales for implantables, consumables, and equi...
8/22/2025
BreakingDealsPharmaRetina
Boehringer Ingelheim, Palatin to Collaborate on Melanocortin Agonist for Retina
Boehringer Ingelheim and Palatin Technologies will collaborate to develop a therapy for retinal diseases in a deal worth up to $320 million for Palatin, the companies announced Aug. 18. Palatin’s p...
8/22/2025
BreakingChinaDealsPharmaRetina
Santen Licenses RemeGen’s Retinal Candidate for Greater China, Asian Countries
RemeGen announced Aug. 18 that Santen China, a subsidiary of Japan’s Santen Pharmaceutical, had licensed retinal treatment candidate RC28-E for Greater China and certain other Asian countries. Reme...
8/20/2025
GlaucomaNewsletterPharma
Weekly Surgeon Poll, August 2025
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.